Click to Share
 

Napsr Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By NAPSRx
The U.S. Food and Drug Administration has approved Praluent (alirocumab) Injection to treat high LDL Cholesterol in adult patients.
12478140
By NAPSRx
The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to Bristol-Myers Squibb’s investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection...
By NAPSRx
The U.S. Food And Drug Administration (FDA) has approved Eisai’s antiepileptic agent Fycompa® (perampanel hydrate) to be used as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and...
By NAPSRx
Johnson & Johnson (Janssen) plans to file regulatory approvals for 10 new products between 2014 and 2019, each with the potential to accumulate $1 billion in revenue plus 40 line extensions of existing and new medicines.
By NAPSRx
In a robust deal worth $8.05 billion, Endo Pharmaceuticals will acquire privately-held Par Pharmaceutical Holdings from TPG.
By NAPSRx
The investigational drug venetoclax has been granted Breakthrough Therapy Designation from the U.S.
By NAPSRx
Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity...
By NAPSRx
Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis.
By NAPSRx
On April 29, 2015, the U.S Food and Drug Administration (FDA) approved KYBELLA (deoxycholic acid) Injection manufactured by Kythera Biopharmaceuticals to improve Submental Fullness, or “Double Chin”.
By NAPSRx
The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted priority review for Abbvie’s all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with...
By NAPSRx
Horizon Pharma plc has announced that ACTIMMUNE® has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA), to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.
By NAPSRx
The U.S. Food and Drug Administration (FDA) has officially greenlighted Regeneron’s EYLEA® (aflibercept) Injection to treat Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) which marks the fourth approved indication for the drug in...
By NAPSRx
Eli Lilly has entered into an exclusive license agreement with Hanmi Pharmaceutical Co., Ltd. to develop and commercialize Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.
By NAPSRx
In an effort to expand their presence in the oncology market and expand their already resilient pipeline, Abbvie will acquire Pharmacyclics  including its blockbuster product Imbruvica, a first class BTK inhibitor approved for hematologic...
12429691
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2...
12417373
By NAPSRx
The US Food and Drug Administration (FDA) has approved Novartis’ new psoriasis treatment Cosentyx (secukinumab) for adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the...
By NAPSRx
SAVAYSA™ (edoxaban) tablets, an oral once-daily selective factor Xa-inhibitor have been approved by the U.S.
By NAPSRx
The U.S Food and Drug Administration has greenlighted Novo Nordisk’s new drug application (NDA) for Saxenda®  a once daily once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for adults who are obese (BMI ≥30 kg/m2) or who are...
12405000
By NAPSRx
A new bill has been presented by U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT)  to develop a new pathway for antibiotic drug approvals called the Promise for Antibiotics and Therapeutics for Health (PATH) Act .This act is anticipated to.
12401504
By NAPSRx
Eli Lilly will obtain an exclusive worldwide license from Zosano Pharma Corporation to commercialize their investigational therapy ZP-PTH intended to treat osteoporosis patients.

All Press Releases

By NAPSRx
The U.S. Food and Drug Administration has approved Praluent (alirocumab) Injection to treat high LDL Cholesterol in adult patients.
12478140
By NAPSRx
The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to Bristol-Myers Squibb’s investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection...
By NAPSRx
The US Food and Drug Administration (FDA) has officially greenlighted Novartis’ heart failure drug Entresto(TM)  formerly known as LCZ696 to treat heart failure with reduced ejection fraction.
By NAPSRx
According to the “EvaluatePharma World Preview 2015, Outlook to 2020” report, prescription sales are expected to increase 5 percent annually over the next five years across the United States  and Europe.
By NAPSRx
The U.S. Food And Drug Administration (FDA) has approved Eisai’s antiepileptic agent Fycompa® (perampanel hydrate) to be used as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and...
By NAPSRx
Allergan plc has agreed to acquire KYTHERA Biopharmaceuticals, Inc for approximately $2.1 billion valued at $75 per KYTHERA share.
By NAPSRx
Johnson & Johnson (Janssen) plans to file regulatory approvals for 10 new products between 2014 and 2019, each with the potential to accumulate $1 billion in revenue plus 40 line extensions of existing and new medicines.
By NAPSRx
In a robust deal worth $8.05 billion, Endo Pharmaceuticals will acquire privately-held Par Pharmaceutical Holdings from TPG.
By NAPSRx
Baxter is ready to expand its oncology segment by acquiring Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A for USD $900 million.
By NAPSRx
The investigational drug venetoclax has been granted Breakthrough Therapy Designation from the U.S.
By NAPSRx
Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity...
By NAPSRx
Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis.
By NAPSRx
On April 29, 2015, the U.S Food and Drug Administration (FDA) approved KYBELLA (deoxycholic acid) Injection manufactured by Kythera Biopharmaceuticals to improve Submental Fullness, or “Double Chin”.
By NAPSRx
Eli Lilly’s breakthrough cancer treatment CYRAMZA® (ramucirumab) has received another approval from the U.S Food and Drug Administration (FDA) making this the fourth approved indication for the treatment.
By NAPSRx
The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted priority review for Abbvie’s all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with...
By NAPSRx
Pfizer has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for  XALKORI® (crizotinib) to potentially treat patients with ROS1-positive non-small cell lung cancer (NSCLC).
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Amgen’s Corlanor® (ivabradine) to treat chronic heart failure.
By NAPSRx
Horizon Pharma plc has announced that ACTIMMUNE® has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA), to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.
By NAPSRx
Bristol-Myers Squibb (BMS) will get exclusive access to uniQure’s gene technology platform based on a strategic collaboration between both companies to identify multiple targets in cardiovascular diseases.
By NAPSRx
ProAir® RespiClick is the first Breath-Actuated Dry-Powder Short-Acting Beta-Agonist (SABA) Inhaler to be approved by the FDA.
By NAPSRx
Jadenu, a new formulation of Exjade (deferasirox) is a simplified daily treatment, administered to patients with chronic iron overload.
By NAPSRx
The U.S. Food and Drug Administration (FDA) has officially greenlighted Regeneron’s EYLEA® (aflibercept) Injection to treat Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) which marks the fourth approved indication for the drug in...
By NAPSRx
AstraZeneca will enter into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI)  in order to acclimatize a technique for the creation of human beta cells from stem cells for use in screens of AstraZeneca’s compound...
By NAPSRx
Eli Lilly has entered into an exclusive license agreement with Hanmi Pharmaceutical Co., Ltd. to develop and commercialize Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.
By NAPSRx
The Dementia Discovery Fund has been established by the UK government to fuel research and development for Dementia which pose a serious threat to public health and healthcare systems globally according to the World Health Organization.
By NAPSRx
Bayer HealthCare striving for strong sales and margin growth through 2017!
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Unituxin (dinutuximab) from the United Therapeutics Corporation as a part of first-line therapy for pediatric patients with high-risk neuroblastoma.
By NAPSRx
In an effort to expand their presence in the oncology market and expand their already resilient pipeline, Abbvie will acquire Pharmacyclics  including its blockbuster product Imbruvica, a first class BTK inhibitor approved for hematologic...
12429691
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2...
By NAPSRx
Voyager Therapeutics and Genzyme, a Sanofi company, have entered into a  collaborative deal to develop treatments aimed at combatting fatal and debilitating diseases affecting the central nervous system (CNS).

Page:
Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share